[Nephrology : What's new in 2016 ?]
The first treatment which slows the course of polycystic kidney disease is now available in Switzerland. There is no benefit of immunosuppression when treating IgA nephropathy. Rituximab has been proved effective in the treatment of membranous nephropathy. When to start renal replacement therapy in acute kidney injury ? The debate still continues. In selected patients with end-stage renal failure, starting with twice a week hemodialysis is a desirable option. Peritoneal dialysis can be considered in frail patients. Better being transplanted with a HLA-incompatible living donor than to be on the waiting list. Immunosuppression without a calcineurin inhibitor is a potential immunologic hazard even for stable transplants. Long-term results of belatacept-based immunosuppression instead of cyclosporin showed better graft and patient survival but more acute rejection.